LITERATUR

1. *Agarwal M et al (2020)* Drug-induced uveitis: A review. Indian J Ophthalmol 68: 1799–1807
2. *Amagai R et al (2024)* Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04. J Dermatol 51: 854–857
3. *Arevalo JF, Mendoza AJ, Ferretti Y (2003)* Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 23: 495–502
4. *Balducci N et al (2016)* Hemorrhagic occlusive retinal vasculitis after first eye cataract surgery without subsequent second eye involvement. Ophthalmic Surg Lasers Imaging Retina 47: 764–766
5. *Benage M, Fraunfelder FW (2016)* Vaccine-associated uveitis. Mo Med 113: 48–52
6. *Bird AC, el-Sheikh H, Anderson J, Fuglsang H (1980)* Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol 64: 191–200
7. *Bouladi M et al (2024)* New onset of uveitis during infliximab treatment: a case report. Tunis Med 102: 58–60
8. *Bringas Calvo R, Iglesias Cortiñas D (2004)* Uveítis anterior aguda bilateral secundaria a moxifloxacino. Arch Soc Esp Oftalmol 79: 357–359
9. *Chartrand NA et al (2023)* Ocular side effects of Bisphosphonates: A review of literature. J Ocul Pharmacol Ther 39: 3–16
10. *Cunningham ET et al (2019)* Vaccine-associated uveitis. Ocul Immunol Inflamm. 27: 517–520
11. *Cunningham ET, Zierhut M (2010)* TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm 18: 421–423
12. *Daïen CI et al, Club Rhumatismes et Inflammation (CRI) (2009)* Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 48: 883–886
13. *Davis JL et al (1997)* Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 115: 733–737
14. *Del-Piñal M et al (2023)* Acute fibrinous anterior uveitis in a patient treated with topical interferon-α2b for ocular surface squamous neoplasia with uveitis susceptibility. Cornea 42: 648–650
15. *Dhar SK et al (2015)* Topiramate-induced bilateral anterior uveitis with choroidal detachment and angle closure glaucoma. Med J Armed Forces India 71: 88–91
16. *Dow ER, Yung M, Tsui E (2021)* Immune checkpoint inhibitor-associated uveitis: Review of treatments and outcomes. Ocul Immunol Inflamm 29: 203–211
17. *Doycheva D, Deuter C, Stübiger N, Zierhut M (2009)* Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 247: 675–680
18. *Etminan M, Forooghian F, Maberley D (2012)* Inflammatory ocular adverse events with the use of oral bisphonates: a retrospective cohort study. CMAJ 15: 431–434
19. *Fiorelli VM, Bhat P, Foster CS (2010)* Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm 18: 116–120
20. *Fonollosa A et al (2012)* Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm 20: 44–48
21. *Francis H, Awadzi K, Ottesen EA (1985)* The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg 34: 529–536
22. *Fraunfelder FT (1996)* Drug-induced ocular side effects. In: Dienthylcarbamazine, 4. Aufl. S. 7–8. Williams & Wilkins, Baltimore,
23. *Garg SJ et al (2019)* Color Atlas and Synopsis of Clinical Ophthalmology: Uveitis. S 338–355. Wolters Kluwer, Philadelphia
24. *Gendelman O, Tripto-Shkolnik L, Vered I, Lidar M (2022)* Bisphosphonates related ocular side effects: A case series and review of literature. Ocul Immunol Inflamm 3: 1995-1999
25. *Greene BM et al (1983)* Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes. J Infect Dis 147: 890–897
26. *Hernanz I et al (2022)* Tuberculosis-related uveitis in patients under anti-TNF-alpha therapy: a case series. Ocul Immunol Inflamm 30: 839–844
27. *Hinkle DM et al (2012)* Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol 31: 111–116
28. *Hustead JD (1991)* Granulomatous uveitis and quinidine hypersensitivity. Am J Ophthalmol 112: 461–462
29. *Iqbal KM, Hay MW, Emami-Naeini P (2021)* Medication-induced uveitis: An Update. J Ophthalmic Vis Res 16: 84–92
30. *Kamal AM et al (2015)* Pegylated interferon-induced sarcoidosis presenting with anterior uveitis in a patient with chronic hepatitis C: Case report. Curr Health Sci J 41: 379–384
31. *Karavellas MP et al (2001)* Immune recovery vitritis and uveitis in AIDS patients with cytomegalovirus retinitis after initiation of HAART. Am J Ophthalmol 131: 518–527
32. *Kato A, Ishihara M, Mizuki N (2021)* Interferon-induced sarcoidosis with uveitis as the initial symptom: A case report and review of the literature. J Med Case Rep 15: 568
33. *Kempen JH et al (2006)* Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 113: 684–694
34. *Keren S et al (2019)* Aminobisphosphonate-associated orbital and ocular inflammatory disease. Acta Ophthalmol 97: 792–799
35. *Kristinsson JK, Hannesson OB, Sveinsson O, Thorleifsson H (1997)* Bilateral anterior uveitis and retinal haemorrhages after administration of trimethoprim. Acta Ophthalmol Scand 75: 314–315
36. *Kunzmann V et al (2000)* Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384–392
37. *Lim LL, Fraunfelder FW, Rosenbaum JT (2007)* Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56: 3248–3252
38. *Liu C, Wang X, Zhou C, Cao X (2025)* A real-world disproportionality analysis of cidofovir from the FDA Adverse Event Reporting System (FAERS) database. Expert Opin Drug Saf, published online April 9
39. *London NJ et al (2013)* Drug-induced uveitis. J Ophthalmic Inflamm Infect 3: 43
40. *Lu LM, Wilkinson VMT, Niederer RL (2025)* Drug-induced uveitis: patterns, pathogenesis and clinical implications. Clin Optom 17: 141–161
41. *Mackensen F, Smith JR, Rosenbaum JT (2007)* Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology 114: 995–999

42. *Manna MS et al (2021)* A trimethoprim derivative impedes antibiotic resistance evolution. Nat Commun 12: 2949
43. *Martens A et al (2023)* Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect 13: 5
44. *Mettler C et al (2021)* Ocular safety profile of BRAF and MEK inhibitors: Data from the World Health Organization Pharmacovigilance Database. Ophthalmology 128: 1748–1755
45. *Miller MA, Lenci LT, Reddy CV, Russell SR (2016)* Postoperative hemorrhagic occlusive retinal vasculitis associated with intracameral vancomycin prophylaxis during cataract surgery. J Cataract Refract Surg 42: 1676–1680
46. *Nair N, Sudharshan S, Koladiya NA, Biswas J (2022)* Rifabutin-induced hypopyon uveitis mimicking endophthalmitis as a manifestation of IRU in patients with HIV. Indian J Pharmacol 54: 67–68
47. *Pathak S, Power B (2007)* Bilateral acute anterior uveitis as a side effect of trimethoprim. Eye (Lond) 21: 252–253
48. *Power WJ et al (1995)* Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 102: 1669–1976
49. *Rodrigues Alves N et al (2024)* Immune recovery uveitis: a focus review. Graefes Arch Clin Exp Ophthalmol 262: 2703–2712
50. *Sankar PS, Pasquale LR, Grosskreutz CL (2001)* Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol 119: 1210–1211
51. *Sauty A et al (1996)* Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18: 133–139
52. *Shen C et al (2022)* Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann Rheum Dis. 8: 875–880
53. *Singla MB, Hodge DK, Moawad FJ (2015)* Infliximab-induced anterior uveitis in a patient with ulcerative colitis. J Crohns Colitis 9: 432
54. *Smith WM et al (2012)* Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect 2: 149–152
55. *Song MK et al (2003)* Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 136: 696–702
56. *Sood S et al (2024)* Segmental retinal arteritis in a case of presumed bilateral rifabutin-associated hypopyon uveitis. Am J Ophthalmol Case Rep 36: 102170
57. *Spitzberg DH (1979)* Acute anterior uveitis secondary to quinidine sensitivity. Arch Ophthalmol 97: 1993
58. *Sultana SS, Jain D, Rao SR (2023)* Case report of diethylcarbamazine induced anterior uveitis with raised intraocular pressure in known case of lymphatic filariasis. Int J Adv Res 11: 1078–1081
59. *Sun MM et al (2020)* Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade linhibition. Ocul Immunol Inflamm 28: 217–227
60. *Takahashi-Watanabe M et al (2024)* Steroid-resistant Vogt-Koyanagi-Harada-like uveitis due to BRAF/MEK inhibitor, successfully treated with adalimumab. Eur J Dermatol 34: 442–444
61. *Tan YL, Sims J, Chee SP (2009)* Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica 223: 215–216
62. *Taylor HR et al (1986)* Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol 104: 863–870
63. *Thng ZX, Li ZK, Gan NY (2021)* Bisphosphonate-induced bilateral anterior uveitis and choroidal effusions with secondary angle closure. Retin Cases Brief Rep 15: 552–555
64. *Tilden ME, Rosenbaum JT, Fraunfelder FT (1991)* Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol 109: 67–69
65. *Todorich B et al (2018)* Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis. Am J Ophthalmol 188: 131–140
66. *Tomkins-Netzer O et al (2022)* Association between vaccination with the BNT162b2 mRNA coronavirus disease 2019 vaccine and non-infectious uveitis: a population-based study. Ophthalmology 129: 1087–1095
67. *Toussirot E, Pertuiset E (2010)* Agents anti-TNFα et sarcoïdose. Rev Med Interne 31: 828–837
68. *Wang F, Wang NS (2009)* Etanercept therapy-associated acute uveitis: a case report and literature review. Clin Exp Rheumatol 27: 838–839
69. *Wang HH, Chung YM, Lin YC, Hu HC, Wong WW (2007)* Rifabutin-induced hypopyon uveitis in patients with acquired immunodeficiency syndrome infected with Mycobacterium avium complex. J Chin Med Assoc 70: 136–139
70. *Wang Q, Wen Z, Cao Q (2016)* Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: a meta-analysis. Exp Ther Med 12: 1693–1704
71. *Witkin AJ et al (2017)* Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes. Ophthalmology 124: 583–595
72. *Witkin AJ et al (2015)* Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology 122: 1438–1451
73. *Xu K et al (2025)* Use of Adalimumab in refractory immune recovery uveitis: a case series. J Clin Ophthalmol 52: 144–149
74. *Yan KK, Dinihan I, Freiman J, Zekry A (2008)* Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for hepatitis C. Intern Med J 38: 207–210
75. *Yanagihara RT, Tom ES, Seitzman GD, Saraf SS (2022)* A case of bilateral multifocal choroiditis associated with BRAF/MEK inhibitor use for metastatic cutaneous melanoma. Ocul Immunol Inflamm 30: 2005–2009
76. *Yang M et al (2023)* Human immunodeficiency virus and uveitis. Viruses 15: 444
77. *Yeo TH (2016)* Immune recovery uveitis in HIV patients with cytomegalovirus retinitis in the era of HAART therapy – a 5-year study from Singapore. J Ophthalmic Inflamm Infect 6: 41
78. *Zhang H, Houadj L, Wu KY, Tran SD (2024)* Diagnosing and managing uveitis associated with immune checkpoint inhibitors: A review. Diagnostics 14: 336
79. *Zhang HA et al (2025)* Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review. J Ophthalmic Inflamm Infect 15: 44
80. *Zierhut M (2010)* Weitere intraokulare Entzündungen. In: Medikamentöse Augentherapie (Hrsg: Erb C, Schlote T) S 244. Thieme, Stuttgart
81. *Zou Y et al (2023)* Ocular inflammation post-vaccination. Vaccines (Basel) 11: 1626
82. *Damasceno EF, Damasceno NAm (2012)* Anterior uveitis after treatment of hepatitis C with alpha interferon: the recurrence of a previous inflammatory process due to presumed ocular toxocariasis. Ocul Immunol Inflamm 20: 53–55